Task: Translation
Input (Czech): 1-(1,2-Disubstituovan² piperidinyl)-4-substituovan  deriv ty piperazinu vzorce I, jejich N-oxidov  formy, jejich farmaceuticky p°ijateln  adi n  soli a jejich stereoizomern  formy, kde n je 0, 1 nebo 2; m je 1 nebo 2, p°i em  kdy  m je 2 pak n je 1; p je 1 nebo 2; =Q je =O nebo =NR.sup.3.n.; X je kovalentn  vazba nebo -O-, -S-, -NR.sup.3.n.-; R.sup.1.n. je Ar.sup.1.n., Ar.sup.1.n.C.sub.1-6.n.alkyl nebo di(Ar.sup.1.n.)C.sub.1-6.n.alkyl, kde ka d  C.sub.1-6.n.alkylskupina je p° padn  substituovan  skupinou zahrnuj c  hydroxy, C.sub.1-4.n.alkyloxy, oxo nebo ketalizovan² oxosubstituent; R.sup.2.n. je Ar.sup.2.n., Ar.sup.2.n.C.sub.1-6.n.alkyl, Het.sup.1.n. nebo Het.sup.1.n.C.sub.1-6.n.alkyl; R.sup.3.n. je vod k nebo C.sub.1-6.n.alkyl; L je vod k; Ar.sup.3.n.; C.sub.1-6.n.alkyl, C.sub.1-6.n.alkyl substituovan² 1 nebo 2 substituenty vybran²mi ze skupiny zahrnuj c  hydroxy, C.sub.1-6.n.alkyloxy, Ar.sup.3.n., Ar.sup.3.n.C.sub.1-6.n.alkyloxy a Het.sup.2.n.; C.sub.3-6.n.alkenyl; Ar.sup.3.n.C.sub.3-6.n.alkenyl; di(Ar.sup.3.n.)C.sub.3-6.n.alkenyl nebo radik l vzorce (a-1),  (a-2), (a-3), (a-4) nebo (a-5); Ar.sup.1.n., Ar.sup.2.n. a Ar.sup.3.n. ka d² znamenaj  fenyl nebo substituovan² fenyl; Het.sup.1.n. a Het.sup.2.n. ka d² znamenaj  monocyklick² nebo bicyklick² heterocyklus; maj c  antagonistick  · inky v  i substanci P; zp sob jejich p° pravy, farmaceutick  kompozice, kter  je obsahuj  a tyto slou eniny pro pou it  jako l  iva.\
Output (English): 1- (1,2-Disubstituted piperidinyl) -4-substituted derivatives of piperazine of formula I, their N-oxides of the form, their pharmaceutically acceptable salts and their stereoisomeric forms, wherein n is 0, 1 or 2; m is 1 or 2, wherein m is 2 then n is 1; p is 1 or 2; = Q is = O or = NR.sup.3; X is a covalent bond or -O-, -S-, -NR.sup.3.n-; R.sup.1.n. is Ar.sup.1, Ar.sup.1.sub.1.sub.1S.sub.1-6alkyl or di (Ar.sub.1.sub.1.sub.1.sub.1-6.sub.6 alkyl); wherein k d C 18 p 1-6 n alkyl is optionally substituted by a group including hydroxy, C 1-3 alkyl alkyloxy, oxo or ketal oxo; R.sup.2.n. is Ar.sup.2, Ar.sup.2.n.C.sub.1-6alkyl, Het.sup.1.n. or Het.sup. R.sup.3.n. is water to C or C 1-6 1-6 alkyl; L is water; Ar.sup.3.n .; C 1-6 alkyl, C 1-6 1-6 alkyl substituted with 1 or 2 substituents selected from the group consisting of c, hydroxy, C 1-6 -alkyloxy, Ar.sup .3n., Ar.sup.3.nCsub.1-6.n.alkyloxy and Het.sup.2.n; C.sub.3-6.n.alkenyl; Ar.sup.3.n.C.sub.3-6.n.alkenyl; di (Ar.sup.3.n) C.sub.3-6.n.alkenyl or radical of formula (a-1), (a-2), (a-3), (a-4) or (a-5); Ar.sup.1.n., Ar.sup.2.n. and Ar.sup.3.n. ka d² is phenyl or substituted phenyl; Het.sup.1.n. a Het.sup.2.n. ka d² is a monocyclic or bicyclic heterocycle; have c antagonists in substance P; the method of their preparation, the pharmaceutical composition containing them and the compounds for use as a nutrient. \ t